BioNews
BioNews operates a network of 50+ rare disease patient community websites reaching 1.5M+ monthly diagnosis-confirmed patients, selling pharmaceutical companies enterprise media advertising, RareSignal market research, clinical trial recruitment, and advocacy partnership services through a direct strategic partnerships sales motion.
- Company typePrivate
- Founded2013
- HeadquartersPensacola, United States
- Headcount101–250
- GTM typeB2B
- OfferingDigital Commerce or Content
What BioNews does
BioNews Inc., founded in 2013 and headquartered at 3 W Garden St, Suite 700, Pensacola, Florida, operates a network of 50+ rare and chronic disease patient community websites that aggregate news, forums, video content, and patient-reported data on conditions including ALS, Friedreich's ataxia, SMA, Myasthenia Gravis, Alzheimer's, and Pompe disease. The platform reaches 1.5M+ monthly engaged patients with a 95% diagnosis-confirmed audience and reports 3-5x industry-average engagement rates and a 7-minute average session duration. The platform's underlying technology stack combines disease-specific community sites with proprietary research assets including RareSignal Intelligence (a patient intelligence product drawing on behavioral data from the 50+ communities), the Rare Trust in AI Index (a quarterly research product tracking patient trust in AI-generated health information), and a recurring nationwide rare disease survey (the 2024 wave reached 5,032 respondents). More than 50% of Bionews employees are living with or caring for someone with a rare condition, which is positioned as a content and community authenticity differentiator.
BioNews generates revenue through four enterprise B2B streams sold to pharmaceutical companies, biotechs, clinical research organizations (CROs), and patient advocacy organizations. Media & Advertising integrates brands into the trusted community environments via eNewsletters, sponsored content, brand pages, and video. Clinical Trial Recruitment Services accelerate rare disease trial enrollment by referring patients matching diagnosis, history, and location, with revenue recognized via referral or service fees. Market Research & Insights (RareSignal) monetizes custom studies, rapid polls, and focus groups as a research service. Advocacy Partnerships & Sponsored Content produces patient storytelling and awareness campaigns. Pricing is bespoke and partnership-based with multi-year contracts; there are no publicly listed tiers or consumer-facing products. Commercial customers named in source material include the top 20 pharmaceutical companies, with specific testimonial evidence from Publicis Health Media, CMI Media Group, Heartbeat Ideas, and Blue Owl Agency (healthcare media agencies) and a Top 10 Pharma VP of Patient Engagement.
The go-to-market motion is direct enterprise field sales with a strategic partnerships team responding to inbound inquiries within one business day, supplemented by presence at the annual World Orphan Drug Congress and hosted webinars including the RWE Series. Distribution is exclusively B2B; the 1.5M+ patient audience is leveraged as the underlying asset driving client value rather than monetized directly to consumers. Distribution is also anchored in the company's owned-media footprint: SEO-optimized disease-specific news sites, owned newsletters, organic social (Facebook, LinkedIn, Instagram), and earned media coverage of proprietary research. Operational footprint is concentrated at the Pensacola headquarters, but the company claims a global audience and serves pharmaceutical clients internationally.
BioNews firmographics
Firmographics- Name
- BioNews
- Legal name
- Bionews Inc.
- Website
- https://mitochondrialdiseasenews.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- BioNews operates a network of 50+ rare disease patient community websites reaching 1.5M+ monthly diagnosis-confirmed patients, selling pharmaceutical companies enterprise media advertising, RareSignal market research, clinical trial recruitment, and advocacy partnership services through a direct strategic partnerships sales motion.
- Ownership category
- akta.pro rank
BioNews industry classification
Industry- Product category
- Rare Disease Patient Media & Insights
- NAICS
- Media Streaming Distribution Services, Social Networks, and Other Media Networks and Content Providers (51621), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Newspaper, Periodical, Book, and Directory Publishers (5131)
- SIC
- Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Health, Wellness & Patient Communities (MPACAJAL)
- akta.pro secondary industries
- Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where BioNews is headquartered
LocationHeadquarters
- HQ city
- Pensacola
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioNews business model
Business model- GTM type
- B2B
- Offering type
- Digital Commerce or Content
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Media & Advertising: Pharma and healthcare brands pay to integrate within Bionews' trusted rare disease communities through targeted solutions including eNewsletters/eBlasts, targeted media, sponsored content hubs, brand pages, video advertising, DSE sponsorship, and awareness month campaigns.
- Clinical Trial Recruitment Services: Bionews accelerates rare disease clinical trial recruitment by reaching engaged, condition-specific patient communities, educating patients and connecting them with trials matching their diagnosis, treatment history, and location — generating referral fees from pharma/biotech clients.
- Market Research & Insights (RareSignal): Custom studies, rapid polls, pulse surveys, focus groups, and market research surveys offered to pharma and biotech partners seeking condition-specific patient intelligence, billed as a research service.
- Advocacy Partnerships & Sponsored Content: Sponsored storytelling, patient collaborations, and awareness initiatives with patient advocacy organizations and pharma partners. Includes editorial and content partnerships and HCP engagement programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise / partnership-based pricing — no public tier list |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels8 records
BioNews product offering
Product offeringCore offering
BioNews operates a digital health media platform that aggregates 50+ rare and chronic disease patient communities into a single network offering news, forums, video content, and patient-reported data. It monetizes this audience by selling targeted Media & Advertising, RareSignal Research & Insights, Clinical Trial Recruitment, and Advocacy Partnerships solutions to pharmaceutical companies, biotechs, CROs, and patient advocacy organizations.
Product overview
BioNews operates as a unified platform consisting of a core network of 50+ rare and chronic disease community websites, supported by integrated service modules for Media & Advertising (targeted brand integration), RareSignal Research & Insights (patient survey and market research capabilities), Clinical Trial Support (patient recruitment), and Advocacy Partnerships. The company also produces branded content products including The Rare Journey immersive storytelling series and the Rare Trust in AI Index research publication. The platform serves both rare disease patients seeking information and pharmaceutical/clinical partners seeking to reach engaged, diagnosis-confirmed patient audiences.
Differentiator
Problem solved
Functional benefit
Products and services
- Rare Disease News & Community Network Network of 50+ rare and chronic disease news and community websites offering breaking research news, patient stories, forums, resource pages, advocacy partnerships, and social connections across conditions including ALS, Alzheimer's, Pompe, SMA, Myasthenia Gravis, and 45+ others. Built for rare disease patients, caregivers, and the pharma/biotech clients seeking to reach diagnosis-confirmed audiences.
- Media & Advertising Targeted media solutions integrating brands within BioNews' trusted rare disease communities through eNewsletters, sponsored content hubs, brand pages, webinars, video content, conference coverage, and patient storytelling, reaching patients in clinical mindset moments. Sold to pharmaceutical and healthcare brand clients.
- RareSignal (Research & Insights) Custom studies, rapid polls, panel development, focus groups, market research surveys, recruitment support, brand perception analysis, competitive analysis, patient input on trial design, and quality of life impact research delivered through BioNews' 50+ rare disease communities. Sold to pharma and biotech partners as a research service.
- Clinical Trial Support Rare disease clinical trial recruitment through education, awareness building, and study design input. Connects patients with trials matching diagnosis, treatment history, and location for faster enrollment and higher retention. Sold to pharma, biotech, and CRO clients.
- Advocacy Partnerships Collaborative programs with patient advocacy organizations to amplify advocacy efforts, expand access to reliable information, and support a more confident and engaged rare disease journey. Includes sponsored storytelling, patient collaborations, awareness initiatives, editorial and content partnerships, and HCP engagement programs.
- The Rare Journey Immersive multimedia storytelling experience showcasing personal patient journey narratives, featuring Matt Lafleur's Friedreich's ataxia journey. Provides support and peer-to-peer connections for rare disease communities.
- Rare Trust in AI Index Proprietary quarterly research index tracking how rare disease patients evaluate AI-generated health information against human-authored sources, providing insights on patient AI adoption and trust patterns across BioNews communities.
Quantifiable outcome
- 3–5x industry-average engagement rate
- +5 more outcomes
Companies that use BioNews
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
BioNews technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability5 records
Feature5 records
BioNews partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered minor and core.
- Digital Medicine Society (DiMe)minorDiMe (Digital Medicine Society) CEO Jennifer Goldsack participated as a panelist in the Bionews RWE Series webinar 'The Future of RWE' on June 23, 2026, discussing real-world evidence trends.
- Parent Project Muscular DystrophyminorMegan Freed, Senior Director of Data & Health Technology Integration at Parent Project Muscular Dystrophy, participated as a panelist in the Bionews RWE Series webinar 'The Future of RWE'.
- Foundation for the National Institutes of Health (FNIH)minorTré LaRosa, Associate Project Manager at the Foundation for the National Institutes of Health, participated as a panelist in the Bionews RWE Series webinar.
- ParexelminorRachel Smith, Vice President of Rare and Genetic Disease at Parexel, participated as a panelist in the Bionews RWE Series webinar.
- Decentralized Trials & Research Alliance (DTRA)minorCraig Lipset, Co-founder of DTRA, participated as a panelist in the Bionews RWE Series webinar discussing real-world evidence and decentralized trials.
- CSL BehringminorMoshe Vardi, MD, Vice President of R&D and Global Head of Clinical Development at CSL Behring, participated as a panelist in the Bionews RWE Series webinar.
- Journal of Participatory MedicineminorAmy Price, MS, MA, MS, DPhil, Editor in Chief of the Journal of Participatory Medicine, participated as a panelist in the Bionews RWE Series webinar 'The RWE Blindspot'.
- Rona's Fun LabminorLindsey Wahlstrom, Co-founder & Chief Momatologist at Rona's Fun Lab, participated as a panelist in the Bionews RWE Series webinar 'The RWE Blindspot'.
- Mayo Clinic PaSAGE Study TeamcoreThe Mayo Clinic PaSAGE (Patient-powered research for Advancement of Gene therapy Evidence) Study Team collaborates with Bionews to advance rare disease awareness and integrate patient voices into the therapeutic research process. PaSAGE is funded by the NIH. Bionews serves as a virtual forum where researchers, policymakers, and patients exchange ideas on gene editing. Marcella Debidda, President of Bionews Patient Insights & Clinical Solutions, participates in NIH-funded deliberative events alongside ethicists, gene therapists, philosophers, policymakers, and genetic counselors.
- Patient Advocacy OrganizationscoreBionews partners with patient advocacy organizations across its 50+ communities to amplify advocacy efforts, expand access to reliable information, and support patient journeys. Bionews provides platforms for advocacy groups to reach patients and contribute resources, forums, and support to communities.
- Top 20 Pharmaceutical Companies (Client Partners)coreBionews counts the top 20 pharmaceutical companies among its client base, providing media, research, and clinical trial recruitment solutions. These partnerships are commercial client relationships where pharma companies pay for access to Bionews' patient communities.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
BioNews competitors and assessment
Company assessmentEmerging players
- Clara Health: Clinical trial access platform focused on improving patient recruitment and trial awareness. Comparable enterprise motion to pharma and CROs though with less emphasis on condition-specific community depth.
- SmartPatients: Online patient community with an embedded clinical trial matching tool and pharma insights offerings. Niche overlap with BioNews on community-driven trial recruitment and patient intelligence.
Direct peers
- BBK Worldwide: Long-standing patient recruitment and engagement agency for clinical trials across therapeutic areas. Comparable enterprise sales motion to pharma and CROs for trial enrollment acceleration.
- WEGO Health: Patient influencer network connecting pharma and biotech with patient leaders across chronic and rare conditions. Closely comparable to BioNews' patient-community and lived-experience model for pharma engagement and insights.
- Rare Patient Voice: Specializes in connecting rare disease patients and caregivers to market research and clinical trial opportunities. Directly competes with BioNews' RareSignal research and clinical trial recruitment offerings in the rare disease vertical.
- Antidote: Clinical trial matching platform that recruits patients from partner communities for sponsors and CROs. Comparable to BioNews' clinical trial recruitment revenue stream and pharma partner motion.
- Inspire: Operates condition-specific patient communities and partners with life sciences companies for research, clinical trial recruitment, and real-world evidence. Directly comparable as a community-platform-to-pharma intermediary.
Broad incumbents
- Healthline: Large general-consumer health media property owned by RVO Health, monetized via pharma advertising and content partnerships. Competes for the same pharma media budgets but without BioNews' diagnosis-confirmed, rare-disease depth.
- WebMD: Broad health information platform with significant pharma media and sponsored content revenue. A large incumbent that competes for pharma media dollars but lacks BioNews' rare disease community authenticity.
Others
- EveryLife Foundation for Rare Diseases: Rare disease policy and advocacy organization that convenes patient communities and engages with pharma/biotech. Adjacent ecosystem participant rather than a commercial competitor, but overlaps on patient-voice and pharma partnerships.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
BioNews social profiles
Digital presenceBioNews financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioNews leadership team
Management profileNumber of profiles
Profiles9 records
BioNews funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioNews M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioNews
What does BioNews do?
BioNews operates a digital health media platform that aggregates 50+ rare and chronic disease patient communities into a single network offering news, forums, video content, and patient-reported data. It monetizes this audience by selling targeted Media & Advertising, RareSignal Research & Insights, Clinical Trial Recruitment, and Advocacy Partnerships solutions to pharmaceutical companies, biotechs, CROs, and patient advocacy organizations.
Is BioNews a public or private company?
BioNews is a private company. It is classified as unknown and is currently operating.
When was BioNews founded?
BioNews was founded in 2013. It employs 101 to 250 people.
Where is BioNews based?
BioNews is headquartered in Pensacola, United States, in the North America region.
How does BioNews make money?
Four revenue lines are on record. Media & Advertising is the primary driver. The others are clinical Trial Recruitment Services, market Research & Insights (RareSignal) and advocacy Partnerships & Sponsored Content.
Who are BioNews's main competitors?
Emerging players on record are Clara Health and SmartPatients. Direct peers are BBK Worldwide, WEGO Health, Rare Patient Voice, Antidote and Inspire. Broad incumbents are Healthline and WebMD. EveryLife Foundation for Rare Diseases is listed as an others.
Does BioNews have an API?
No public API is recorded for BioNews.
What industry is BioNews in?
BioNews's product category is Rare Disease Patient Media & Insights. Its primary akta.pro industry code is MPACAJAL, Health, Wellness & Patient Communities, with a secondary code of HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D). Its NAICS code is 51621 and its SIC code is 8000.